maud charpentier

[Nils-Petter Rudqvist @NP_Rudqvist]

Our paper on RT+CTLA4+CD40 in hard-to-treat tumors is out in @NatureComms! In-depth analysis of 4T1 tumors treated with RT+CTLA4 and demonstration of CD40 as best companion IO in this setting. Thanks to all co-authors and especially @CharpentierMaud and @DemariaLab_WCM!

[Michels Judith @MichelsJudith]

What a great brainstorm of ideas and common ground for collaborations in the field of Immunotherapy and Radiotherapy Combination. A big Thank you to the Forbeck Research Foundation for brining us together. 'The hope is to shorten the cancer research timetable.' @ForbeckResearch